Financial Analysis: Cancer Genetics (CGIX) versus Its Rivals
Cancer Genetics (NASDAQ: CGIX) is one of 50 publicly-traded companies in the “Healthcare Facilities & Services” industry, but how does it weigh in compared to its rivals? We will compare Cancer Genetics to similar businesses based on the strength of its risk, earnings, dividends, profitability, analyst recommendations, valuation and institutional ownership.
Volatility & Risk
Cancer Genetics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Cancer Genetics’ rivals have a beta of 1.02, meaning that their average share price is 2% more volatile than the S&P 500.
Valuation & Earnings
This table compares Cancer Genetics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cancer Genetics||$27.55 million||-$11.12 million||-2.76|
|Cancer Genetics Competitors||$5.89 billion||$843.94 million||34.36|
Cancer Genetics’ rivals have higher revenue and earnings than Cancer Genetics. Cancer Genetics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current recommendations for Cancer Genetics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cancer Genetics Competitors||265||1573||1967||38||2.46|
Cancer Genetics currently has a consensus price target of $6.00, indicating a potential upside of 106.90%. As a group, “Healthcare Facilities & Services” companies have a potential downside of 6.41%. Given Cancer Genetics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Cancer Genetics is more favorable than its rivals.
Insider and Institutional Ownership
16.1% of Cancer Genetics shares are owned by institutional investors. Comparatively, 69.8% of shares of all “Healthcare Facilities & Services” companies are owned by institutional investors. 21.3% of Cancer Genetics shares are owned by insiders. Comparatively, 14.8% of shares of all “Healthcare Facilities & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Cancer Genetics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cancer Genetics Competitors||9.07%||0.33%||0.50%|
Cancer Genetics rivals beat Cancer Genetics on 7 of the 12 factors compared.
Cancer Genetics Company Profile
Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.
Receive News & Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.